Delivering quality therapy since 1901


​Biotechnology is of a strategic importance for Gedeon Richter. In 2006 the Company took the decision to enter the field of recombinant biotechnology leveraging its more than 50 years of experience accumulated in the steroid fermentation processes.


Full set of capabilities in Biotechnology

In 2007 Gedeon Richter together with Helm AG founded Richter-Helm Biologics Joint venture (JV) in Germany. The JV  embraces state-of-the facilities specialised in microbial cell fermentation technologies: FDA and EMA approved R&D laboratories in Hamburg, cGMP pilot plant capacities in Hannover and FDA and EMA approved drug substance manufacturing plant in Bovenau.

Gedeon Richter also has significant capacities in mammalian cell fermentation based technologies. In 2007 the first mammalian cell development R&D laboratories and a cGMP pilot plant were established in the Company's Budapest site. In 2008 Richter launched a green-field investment to build a plant in Debrecen in order to create the conditions for the manufacturing of mammalian cell products at commercial scale. The drug substance and fill-and-finish manufacturing plants were put into service in 2012.

Thanks to these investments too, Gedeon Richter's activities in biotechnology encompass the full in-house value chain, ranging from research and development through manufacturing to commercialization in key geographical areas.


Current biotechnology portfolio

Product Indication Status
BEMFOLA (biosimilar r-hFSH)InfertilityRichter acquired the product in 2016, marketed in more than 30 countries 
TERROSA (biosimilar teriparatide)Postmenopausal osteoporosisEU marketing authorization received in January 2017
Pegfilgrastim Neutropenia Peg-GCSF EMA MAA filed
Rituximabvarious forms of cancer and auto-immune diseases

Late stage clinical development


TrastuzumabCertain forms of breast cancer and gastric cancerLicensed-in and technology transfer  development project

Further 3 ongoing biosimilar projects in early stage


Partnering with us

The Company's Biotechnology Business Unit has been continuously seeking new partnerships in order to:

  • Leverage R&D, manufacturing and commercialization skills via in-licensing and co-development & co-commercialization in Europe, CIS  and Latin-America. Our areas of interest are:
      • Oncology
      • Osteoporosis
      • Women's Healthcare
      • Niche indications/orphans
  • Secure co-development and commercialization agreements for Gedeon Richter's biosimilar portfolio for the following geographic areas:
      • USA & Canada
      • Asia
      • Australia and New Zealand
      • MENA, Africa

Contact us

Dr. Johanna Knospe

Head of Biotechnology Business Development Department


Phone: +36-1-431-4928


Zsuzsanna Molnár

Senior Business Analyst, Biotechnology Business Development Department


Phone: +36-1-889-8647